New	New	JJ	B-NP	O	
one-week	one-week	JJ	I-NP	O	
,	,	,	I-NP	O	
low-dose	low-dose	JJ	I-NP	O	
triple	triple	JJ	I-NP	O	
therapy	therapy	NN	I-NP	O	
for	for	IN	B-PP	O	
the	the	DT	B-NP	O	
treatment	treatment	NN	I-NP	O	
of	of	IN	B-PP	O	
duodenal	duodenal	JJ	B-NP	O	
ulcer	ulcer	NN	I-NP	O	
with	with	IN	B-PP	O	
Helicobacter pylori	Helicobacter_pylori	NNP	B-NP	O	
infection	infection	NN	I-NP	O	
.	.	.	O	O	

Antimicrobial	Antimicrobial	JJ	B-NP	O	
therapy	therapy	NN	I-NP	O	
is	be	VBZ	B-VP	O	
the	the	DT	B-NP	O	
recommended	recommend	VBN	I-NP	O	
treatment	treatment	NN	I-NP	O	
for	for	IN	B-PP	O	
duodenal	duodenal	JJ	B-NP	O	
ulcer	ulcer	NN	I-NP	O	
associated	associate	VBN	B-VP	O	
with	with	IN	B-PP	O	
Helicobacter pylori	Helicobacter_pylori	NNP	B-NP	O	
infection	infection	NN	I-NP	O	
.	.	.	O	O	

The	The	DT	B-NP	O	
eradication	eradication	NN	I-NP	O	
of	of	IN	B-PP	O	
bismuth	bismuth	NN	B-NP	O	
-	-	HYPH	O	O	
based	base	VBN	B-NP	O	
triple	triple	JJ	I-NP	O	
therapy	therapy	NN	I-NP	O	
with	with	IN	B-PP	O	
bismuth	bismuth	JJ	B-NP	O	
subcitrate	subcitrate	NN	I-NP	O	
,	,	,	I-NP	O	
metronidazole	metronidazole	NN	I-NP	O	
and	and	CC	I-NP	O	
amoxicillin	amoxicillin	NN	I-NP	O	
is	be	VBZ	B-VP	O	
limited	limit	VBN	I-VP	O	
by	by	IN	B-PP	O	
low	low	JJ	B-NP	O	
compliance	compliance	NN	I-NP	O	
,	,	,	O	O	
drug	drug	NN	B-NP	O	
resistance	resistance	NN	I-NP	O	
and	and	CC	I-NP	O	
side	side	NN	I-NP	O	
-	-	HYPH	B-NP	O	
effects	effect	NNS	I-NP	O	
.	.	.	O	O	

Two-week	Two-week	JJ	B-NP	O	
proton	proton	NN	I-NP	O	
pump	pump	NN	I-NP	O	
inhibitor	inhibitor	NN	I-NP	O	
(	(	(	O	O	
PPI	PPI	NN	B-NP	O	
)	)	)	O	O	
-	-	HYPH	O	O	
based	base	VBN	B-NP	O	
triple	triple	JJ	I-NP	O	
therapy	therapy	NN	I-NP	O	
has	have	VBZ	B-VP	O	
a	a	DT	B-NP	O	
higher	high	JJR	I-NP	O	
eradication	eradication	NN	I-NP	O	
rate	rate	NN	I-NP	O	
but	but	CC	O	O	
is	be	VBZ	B-VP	O	
costly	costly	JJ	B-ADJP	O	
.	.	.	O	O	

This	This	DT	B-NP	O	
study	study	NN	I-NP	O	
was	be	VBD	B-VP	O	
designed	design	VBN	I-VP	O	
to	to	TO	B-VP	O	
compare	compare	VB	I-VP	O	
the	the	DT	B-NP	O	
efficacy	efficacy	NN	I-NP	O	
,	,	,	O	O	
patient	patient	NN	B-NP	O	
compliance	compliance	NN	I-NP	O	
and	and	CC	I-NP	O	
cost	cost	NN	I-NP	O	
of	of	IN	B-PP	O	
short	short	JJ	B-NP	O	
-	-	HYPH	I-NP	O	
term	term	NN	I-NP	O	
PPI	PPI	NN	I-NP	O	
-	-	HYPH	B-VP	O	
based	base	VBN	B-NP	O	
triple	triple	JJ	I-NP	O	
therapy	therapy	NN	I-NP	O	
with	with	IN	B-PP	O	
those	those	DT	B-NP	O	
of	of	IN	B-PP	O	
bismuth	bismuth	NN	B-NP	O	
-	-	HYPH	O	O	
based	base	VBN	B-NP	O	
triple	triple	JJ	I-NP	O	
therapy	therapy	NN	I-NP	O	
.	.	.	O	O	

Ninety	Ninety	CD	B-NP	O	
patients	patient	NNS	I-NP	O	
with	with	IN	B-PP	O	
active	active	JJ	B-NP	O	
duodenal	duodenal	JJ	I-NP	O	
ulcer	ulcer	NN	I-NP	O	
disease	disease	NN	I-NP	O	
and	and	CC	O	O	
H pylori	H_pylori	NN	B-NP	O	
infection	infection	NN	I-NP	O	
,	,	,	O	O	
proven	prove	VBN	B-VP	O	
with	with	IN	B-PP	O	
the	the	DT	B-NP	O	
13C	13C	NN	I-NP	O	
-	-	HYPH	B-NP	O	
urea	urea	NN	I-NP	O	
breath	breath	NN	I-NP	O	
test	test	NN	I-NP	O	
and	and	CC	O	O	
CLO	CLO	NN	B-NP	O	
test	test	NN	I-NP	O	
(	(	(	O	O	
Campylobacter	Campylobacter	NN	B-NP	O	
-	-	HYPH	B-NP	O	
like	like	JJ	I-NP	O	
organism	organism	NN	I-NP	O	
test	test	NN	I-NP	O	
)	)	)	O	O	
were	be	VBD	B-VP	O	
treated	treat	VBN	I-VP	O	
randomly	randomly	RB	B-ADVP	O	
in	in	IN	B-PP	O	
three	three	CD	B-NP	O	
therapeutic	therapeutic	JJ	I-NP	O	
groups	group	NNS	I-NP	O	
:	:	:	O	O	
Group	Group	NN	B-NP	O	
A	A	NN	I-NP	O	
,	,	,	O	O	
DeNol	DeNol	NN	B-NP	O	
120	120	CD	I-NP	O	
mg	mg	NN	I-NP	O	
,	,	,	O	O	
amoxicillin	amoxicillin	NN	B-NP	O	
500	500	CD	I-NP	O	
mg	mg	NN	I-NP	O	
and	and	CC	I-NP	O	
metronidazole	metronidazole	NN	I-NP	O	
250	250	CD	I-NP	O	
mg	mg	NN	I-NP	O	
four	four	CD	B-NP	O	
times	time	NNS	I-NP	O	
a	a	DT	B-NP	O	
day	day	NN	I-NP	O	
orally	orally	RB	B-ADVP	O	
for	for	IN	B-PP	O	
14	14	CD	B-NP	O	
days	day	NNS	I-NP	O	
;	;	:	O	O	
Group	Group	NN	B-NP	O	
B	B	NN	I-NP	O	
,	,	,	O	O	
omeprazole	omeprazole	NN	B-NP	O	
20	20	CD	I-NP	O	
mg	mg	NN	I-NP	O	
plus	plus	CC	O	O	
clarithromycin	clarithromycin	NN	B-NP	O	
500	500	CD	I-NP	O	
mg	mg	NN	I-NP	O	
twice	twice	RB	B-NP	O	
a	a	DT	I-NP	O	
day	day	NN	I-NP	O	
and	and	CC	O	O	
amoxicillin	amoxicillin	NN	B-NP	O	
500	500	CD	B-NP	O	
mg	mg	NN	I-NP	O	
four	four	CD	B-NP	O	
times	time	NNS	I-NP	O	
a	a	DT	B-NP	O	
day	day	NN	I-NP	O	
for	for	IN	B-PP	O	
14	14	CD	B-NP	O	
days	day	NNS	I-NP	O	
;	;	:	O	O	
Group	Group	NN	B-NP	O	
C	C	NN	I-NP	O	
,	,	,	O	O	
omeprazole	omeprazole	NN	B-NP	O	
20	20	CD	I-NP	O	
mg	mg	NN	I-NP	O	
,	,	,	O	O	
clarithromycin	clarithromycin	NN	B-NP	O	
250	250	CD	I-NP	O	
mg	mg	NN	I-NP	O	
and	and	CC	I-NP	O	
metronidazole	metronidazole	NN	I-NP	O	
500	500	CD	I-NP	O	
mg	mg	NN	I-NP	O	
twice	twice	RB	B-NP	O	
a	a	DT	I-NP	O	
day	day	NN	I-NP	O	
for	for	IN	B-PP	O	
seven	seven	CD	B-NP	O	
days	day	NNS	I-NP	O	
.	.	.	O	O	

Nizatidine	Nizatidine	NN	B-NP	O	
150	150	CD	I-NP	O	
mg	mg	NN	I-NP	O	
twice	twice	RB	B-NP	O	
a	a	DT	I-NP	O	
day	day	NN	I-NP	O	
was	be	VBD	B-VP	O	
given	give	VBN	I-VP	O	
continuously	continuously	RB	B-ADVP	O	
following	follow	VBG	B-PP	O	
the	the	DT	B-NP	O	
end	end	NN	I-NP	O	
of	of	IN	B-PP	O	
anti	anti	AFX	B-NP	O	
-	-	HYPH	I-NP	O	
H pylori	H_pylori	NN	I-NP	O	
therapy	therapy	NN	I-NP	O	
for	for	IN	B-PP	O	
each	each	DT	B-NP	O	
group	group	NN	I-NP	O	
.	.	.	O	O	

Two	Two	CD	B-NP	O	
months	month	NNS	I-NP	O	
later	later	RB	B-ADVP	O	
,	,	,	O	O	
endoscopy	endoscopy	NN	B-NP	O	
,	,	,	O	O	
the	the	DT	B-NP	O	
CLO	CLO	NNP	I-NP	O	
test	test	NN	I-NP	O	
and	and	CC	I-NP	O	
13C	13C	NN	I-NP	O	
-	-	HYPH	B-NP	O	
urea	urea	NN	I-NP	O	
breath	breath	NN	I-NP	O	
test	test	NN	I-NP	O	
were	be	VBD	B-VP	O	
repeated	repeat	VBN	I-VP	O	
to	to	TO	B-VP	O	
assess	assess	VB	I-VP	O	
the	the	DT	B-NP	O	
eradication	eradication	NN	I-NP	O	
rate	rate	NN	I-NP	O	
of	of	IN	B-PP	O	
H pylori	H_pylori	NNP	B-NP	O	
and	and	CC	O	O	
the	the	DT	B-NP	O	
ulcer	ulcer	NN	I-NP	O	
-	-	HYPH	O	O	
healing	heal	VBG	B-VP	O	
rate	rate	NN	B-NP	O	
.	.	.	O	O	

Drug	Drug	NN	B-NP	O	
tolerance	tolerance	NN	I-NP	O	
was	be	VBD	B-VP	O	
evaluated	evaluate	VBN	I-VP	O	
by	by	IN	B-PP	O	
patients	patient	NNS	B-NP	O	
themselves	themselves	PRP	B-NP	O	
by	by	IN	B-PP	O	
daily	daily	JJ	B-NP	O	
recording	recording	NN	I-NP	O	
of	of	IN	B-PP	O	
any	any	DT	B-NP	O	
side	side	NN	I-NP	O	
-	-	HYPH	B-NP	O	
effects	effect	NNS	I-NP	O	
.	.	.	O	O	

Eighty	Eighty	CD	B-NP	O	
-	-	HYPH	I-NP	O	
four	four	CD	I-NP	O	
patients	patient	NNS	I-NP	O	
completed	complete	VBD	B-VP	O	
the	the	DT	B-NP	O	
entire	entire	JJ	I-NP	O	
course	course	NN	I-NP	O	
of	of	IN	B-PP	O	
therapy	therapy	NN	B-NP	O	
and	and	CC	I-NP	O	
evaluation	evaluation	NN	I-NP	O	
for	for	IN	B-PP	O	
H pylori	H_pylori	NNP	B-NP	O	
infection	infection	NN	I-NP	O	
.	.	.	O	O	

The	The	DT	B-NP	O	
H pylori	H_pylori	NNP	I-NP	O	
eradication	eradication	NN	I-NP	O	
rates	rate	NNS	I-NP	O	
in	in	IN	B-PP	O	
Groups	Group	NNS	B-NP	O	
A	A	NN	I-NP	O	
,	,	,	O	O	
B	B	NN	B-NP	O	
and	and	CC	O	O	
C	C	NN	B-NP	O	
were	be	VBD	B-VP	O	
75%	75%	CD	B-NP	O	
(	(	(	O	O	
21/28	21/28	CD	B-NP	O	
)	)	)	O	O	
,	,	,	O	O	
93%	93%	CD	B-NP	O	
(	(	(	O	O	
26/28	26/28	CD	B-NP	O	
)	)	)	O	O	
and	and	CC	O	O	
89%	89%	CD	B-NP	O	
(	(	(	O	O	
25/28	25/28	CD	B-NP	O	
)	)	)	O	O	
,	,	,	O	O	
respectively	respectively	RB	B-ADVP	O	
(	(	(	O	O	
p	p	NN	B-NP	O	
=	=	SYM	B-VP	O	
0.466	0.466	CD	B-NP	O	
)	)	)	O	O	
.	.	.	O	O	

The	The	DT	B-NP	O	
ulcer	ulcer	NN	I-NP	O	
healing	healing	NN	I-NP	O	
rate	rate	NN	I-NP	O	
was	be	VBD	B-VP	O	
86%	86%	CD	B-NP	O	
(	(	(	O	O	
24/28	24/28	CD	B-NP	O	
)	)	)	O	O	
in	in	IN	B-PP	O	
Group	Group	NN	B-NP	O	
A	A	NN	I-NP	O	
and	and	CC	O	O	
89%	89%	NN	B-NP	O	
(	(	(	O	O	
25/28	25/28	CD	B-NP	O	
)	)	)	O	O	
in	in	IN	B-PP	O	
Groups	Group	NNS	B-NP	O	
B	B	NN	B-NP	O	
and	and	CC	O	O	
C	C	NN	B-NP	O	
(	(	(	O	O	
p	p	NN	B-NP	O	
=	=	SYM	B-VP	O	
0.764	0.764	CD	B-NP	O	
)	)	)	O	O	
.	.	.	O	O	

A	A	DT	B-NP	O	
total	total	NN	I-NP	O	
of	of	IN	B-PP	O	
74	74	CD	B-NP	O	
patients	patient	NNS	I-NP	O	
(	(	(	O	O	
88%	88%	NN	B-NP	O	
)	)	)	O	O	
were	be	VBD	B-VP	O	
free	free	JJ	B-ADJP	O	
from	from	IN	B-PP	O	
symptoms	symptom	NNS	B-NP	O	
at	at	IN	B-PP	O	
the	the	DT	B-NP	O	
end	end	NN	I-NP	O	
of	of	IN	B-PP	O	
the	the	DT	B-NP	O	
triple	triple	JJ	I-NP	O	
therapy	therapy	NN	I-NP	O	
.	.	.	O	O	

Symptom	Symptom	NN	B-NP	O	
relief	relief	NN	I-NP	O	
was	be	VBD	B-VP	O	
faster	fast	JJR	B-ADJP	O	
in	in	IN	B-PP	O	
patients	patient	NNS	B-NP	O	
with	with	IN	B-PP	O	
PPI	PPI	NN	B-NP	B-protein	
-	-	HYPH	O	O	
based	base	VBN	B-VP	O	
triple	triple	JJ	B-NP	O	
therapy	therapy	NN	I-NP	O	
(	(	(	O	O	
Groups	Group	NNS	B-NP	O	
B	B	NN	B-NP	O	
and	and	CC	O	O	
C	C	NN	B-NP	O	
)	)	)	O	O	
(	(	(	O	O	
days	day	NNS	B-NP	O	
3	3	CD	B-NP	O	
and	and	CC	I-NP	O	
4	4	CD	I-NP	O	
)	)	)	O	O	
than	than	IN	B-PP	O	
for	for	IN	B-PP	O	
patients	patient	NNS	B-NP	O	
with	with	IN	B-PP	O	
bismuth	bismuth	NN	B-NP	O	
-	-	HYPH	O	O	
based	base	VBN	B-VP	O	
triple	triple	JJ	B-NP	O	
therapy	therapy	NN	I-NP	O	
(	(	(	O	O	
day	day	NN	B-NP	O	
5	5	CD	I-NP	O	
)	)	)	O	O	
.	.	.	O	O	

The	The	DT	B-NP	O	
cost	cost	NN	I-NP	O	
of	of	IN	B-PP	O	
Group	Group	NN	B-NP	O	
C	C	NN	I-NP	O	
therapy	therapy	NN	I-NP	O	
was	be	VBD	B-VP	O	
lower	low	JJR	B-ADJP	O	
than	than	IN	B-PP	O	
that	that	DT	B-NP	O	
for	for	IN	B-PP	O	
Groups	Group	NNS	B-NP	O	
A	A	NN	I-NP	O	
and	and	CC	I-NP	O	
B	B	NN	I-NP	O	
.	.	.	O	O	

There	There	EX	B-NP	O	
were	be	VBD	B-VP	O	
no	no	DT	B-NP	O	
major	major	JJ	I-NP	O	
side	side	NN	I-NP	O	
-	-	HYPH	I-NP	O	
effects	effect	NNS	I-NP	O	
in	in	IN	B-PP	O	
any	any	DT	B-NP	O	
of	of	IN	B-PP	O	
the	the	DT	B-NP	O	
patients	patient	NNS	I-NP	O	
.	.	.	O	O	

One-week	One-week	JJ	B-NP	O	
triple	triple	JJ	I-NP	O	
therapy	therapy	NN	I-NP	O	
with	with	IN	B-PP	O	
omeprazole	omeprazole	NN	B-NP	O	
,	,	,	I-NP	O	
clarithromycin	clarithromycin	NN	I-NP	O	
and	and	CC	I-NP	O	
metronidazole	metronidazole	NN	I-NP	O	
is	be	VBZ	B-VP	O	
highly	highly	RB	I-VP	O	
effected	effect	VBN	I-VP	O	
for	for	IN	B-PP	O	
the	the	DT	B-NP	O	
eradication	eradication	NN	I-NP	O	
of	of	IN	B-PP	O	
H pylori	H_pylori	NNP	B-NP	O	
.	.	.	O	O	

A	A	DT	B-NP	O	
therapeutic	therapeutic	JJ	I-NP	O	
regime	regime	NN	I-NP	O	
of	of	IN	B-PP	O	
one	one	CD	B-NP	O	
week's	week'	NNS	I-NP	O	
duration	duration	NN	I-NP	O	
with	with	IN	B-PP	O	
lower	low	JJR	B-NP	O	
cost	cost	NN	I-NP	O	
,	,	,	O	O	
good	good	JJ	B-NP	O	
compliance	compliance	NN	I-NP	O	
and	and	CC	O	O	
mild	mild	JJ	B-NP	O	
side	side	NN	I-NP	O	
-	-	HYPH	B-NP	O	
effects	effect	NNS	I-NP	O	
may	may	MD	B-VP	O	
offer	offer	VB	I-VP	O	
a	a	DT	B-NP	O	
good	good	JJ	I-NP	O	
choice	choice	NN	I-NP	O	
for	for	IN	B-PP	O	
treatment	treatment	NN	B-NP	O	
of	of	IN	B-PP	O	
duodenal	duodenal	JJ	B-NP	O	
ulcer	ulcer	NN	I-NP	O	
associated	associate	VBN	B-VP	O	
with	with	IN	B-PP	O	
H pylori	H_pylori	NN	B-NP	O	
infection	infection	NN	I-NP	O	
in	in	IN	B-PP	O	
clinical	clinical	JJ	B-NP	O	
practice	practice	NN	I-NP	O	
.	.	.	O	O	

